Analyst Amit Tandon gives Peak a speculative rating, and a target price of $1.26, a premium of 404% to the $0.25 price the day the report was issued. Based in Boulder, Colorado, Peak Pharmaceuticals is developing safe, hemp-based medicinal products targeting the human and animal nutraceutical and supplements markets.
